Phase I-II study of liposomal doxorubicin (Myocet), docetaxel and trastuzumab as first-line treatment of patients with HER-2 [human epidermal growth receptor 2]/Neu positive metastatic breast cancer

Trial Profile

Phase I-II study of liposomal doxorubicin (Myocet), docetaxel and trastuzumab as first-line treatment of patients with HER-2 [human epidermal growth receptor 2]/Neu positive metastatic breast cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Doxorubicin liposomal (Primary) ; Docetaxel; Trastuzumab
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Sponsors Zenus Pharma
  • Most Recent Events

    • 27 Jul 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top